New Delhi, February 7, 2025: Akums Drugs and Pharmaceuticals Ltd., has announced its consolidated financial results for the quarter ended December 31, 2024, delivering 12% increase in Adjusted EBITDA on year on year basis.
Key Highlights:
| Quarter ended December 31, 2024 | 9 months ended December 31, 2024 |
| • Adj EBITDA Margin at 13.3%| Adj PAT Margin at 6.5%
• Adjusted EBITDA of Rs 1,359 million |up 12.1% YoY | up 0.9% QoQ • Total Income at Rs 10,250 million |decline of 6.1% YoY | decline of 2.1% QoQ • Adjusted PAT of Rs 663 million | up 15.2% YoY | decline of 0.5% QoQ |
• Adj EBITDA Margin at 13.0%| Adj PAT Margin at 6.1%
• Adjusted EBITDA of Rs 4,013 million | down 3.6% YoY • Total Income at Rs 30,972 million | Reduction of 4.9% YoY • Adjusted PAT of Rs 1,903 million | up 9% YoY |
| Segmental | Segmental |
| • CDMO EBITDA of Rs 1,214 million |up 9.2% YoY| down 1.1% QoQ
• Branded and Generic EBITDA of Rs 198 million |down 17.1% YoY| up 9.9% QoQ • API EBITDA at Rs -109 million |
• CDMO EBITDA margin Rs 3,652 million robust at 15.4%
• Branded and Generic EBITDA margin Rs 549 million at 10.5% • API EBITDA at Rs -373 million |
For Q3, Operating performance of the company was robust with overall Adj EBITDA growing 12% YoY and Adj PAT growing 15% YoY driven by better profitability in our core CDMO segment. The EBITDA improvement shows our continued improvement in the product mix. API EBITDA losses reduced significantly in Q3 YoY, although prices of cephalosporin APIs still remain low. Additionally, branded formulation business continues to perform well across domestic and export markets.
Sanjeev Jain, Managing Director, also shared his views, stating, “Q3 was an exciting quarter for the company. With our focus on establishing Akums’ global CDMO footprint, we took a significant step by securing a €200 million contract. The contract involves manufacture and supply of products to be sold in European markets. We believe this is the first of many partnerships we will undertake to serve the European market in the years to come.”
Sandeep Jain, Managing Director, stated, “We continue to be the manufacturing partners of choice for pharmaceutical companies. We have started to see volume green shoots in Q3 compared to Q2. We also in-licensed novel products of Triple hair and Caregen in dermatology and metabolic segment to drive future growth.”
